Bioceres Crop Solutions Corp. (BIOX) Stock: Price, Forecast & Analyst Target
Bioceres Crop Solutions Corp. (BIOX) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $0.201 (+5.73%), as of the Nov 18, 2026 trading session; market cap $12.8M.
Educational signal · not a buy or sell recommendation · How to read this
Bioceres Crop Solutions Corp. · BIOX · NASDAQ
Bioceres Crop Solutions Corp. provides crop productivity solutions through seed and integrated products, crop protection, and crop nutrition. The company operates internationally, focusing on developing and commercializing technologies for enhanced agricultural outcomes.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Bioceres Crop Solutions (BIOX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.
- EPS beat 0 of the last 4 reports
- Altman Z 0.35 · Piotroski F 3
- ROE -56.8% · ROA -2.0% · current ratio 0.70
Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.201 | |
| Change on the day | +5.73% | |
| Market capitalisation | $12.8M | — |
| Shares traded on the day | 190.7K |
Price & events
Other perspectives
Council score for Bioceres Crop Solutions (BIOX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Bioceres Crop Solutions (BIOX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Bioceres Crop Solutions Corp. (BIOX) is listed on NASDAQ. It employs 562 people. The market values it at $12.8M.
What do the latest results show for Bioceres Crop Solutions (BIOX)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $74M | -$48M | -$0.76 (diluted) |
| Q1 FY2026 | $77M | -$7M | -$0.12 (diluted) |
| Q2 FY2026 | $74M | -$183M | -$2.88 (diluted) |
| Q3 FY2026 | $38M | -$9M | -$0.14 (diluted) |
What are the financial strengths and risks for Bioceres Crop Solutions (BIOX)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z 0.35 · Piotroski F 3. Trailing ratios: ROE -56.8% · ROA -2.0% · current ratio 0.70.
Data-derived red flags
- Listing risk — at $0.201 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of 0.35 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-56.8%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Bioceres Crop Solutions (BIOX)?
Short answer · as of
Current published price targets run low $2.00 · high $2.00 · consensus $2.00 · median $2.00 against a quoted price of $0.201 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Bioceres Crop Solutions compare with its peers?
Short answer
Bioceres Crop Solutions's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $113.70 Nov 18, 2026 | $16.6B | 98 5-pillar Nov 18, 2026 | |
| $29.96 Nov 18, 2026 | $400M | 77 5-pillar Nov 18, 2026 | |
| $95.53 Nov 18, 2026 | $1.10B | 70 5-pillar Nov 18, 2026 | |
| $65.92 Nov 18, 2026 | $31.3B | 70 5-pillar Nov 18, 2026 | |
| $4.19 Nov 18, 2026 | $5.69B | 62 5-pillar Nov 18, 2026 | |
| $64.09 Nov 18, 2026 | $3.73B | 58 5-pillar Nov 18, 2026 | |
| $8.36 Nov 18, 2026 | $5.58B | 51 5-pillar Nov 18, 2026 | |
| $9.37 Nov 18, 2026 | $178M | 42 5-pillar Nov 18, 2026 | |
| $7.95 Nov 18, 2026 | $2.21B | 42 5-pillar Nov 18, 2026 | |
| $0.76 Nov 18, 2026 | $22.4M | 37 5-pillar Nov 18, 2026 | |
| Bioceres Crop Solutions (BIOX) — this page | $0.201 | $12.8M | 35 |
| $19.93 Nov 18, 2026 | $6.34B | 35 5-pillar Nov 18, 2026 | |
| $4.68 Nov 18, 2026 | $728M | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $2.00 – $2.00
- Consensus target
- $2.00
- Median target
- $2.00
Consensus record · Captured .
Measured against a quoted price of $0.201 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 3
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 0
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BIOX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BIOX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bioceres Crop Solutions (BIOX)?
- Bioceres Crop Solutions Reports Fiscal First Quarter 2027 Financial Results
- Bioceres Crop: Fiscal Q1 Earnings Snapshot
- Bioceres Crop Solutions Q1 EPS $(0.17) Misses $(0.10) Estimate, Sales $53.800M Down From $69.100M YoY
- Bioceres Crop Solutions Q1 EPS $(0.17) Misses $(0.10) Estimate, Sales $53.800M Down From $77.300M YoY
Investor Questions: BIOX Stock
These answers are editorial: 1 of these 9 answers is drawn from the BIOX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BIOX?
BIOX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Bioceres Crop Solutions Corp. provides crop productivity solutions through seed and integrated products, crop protection, and crop nutrition.
Is BIOX a good stock to buy?
Stock Expert AI does not rate BIOX buy, sell or hold. Bioceres Crop Solutions Corp. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BIOX stock price today?
The last price recorded for Bioceres Crop Solutions Corp. (BIOX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BIOX price target?
The analyst consensus price target for Bioceres Crop Solutions Corp. (BIOX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for BIOX?
The main risks for BIOX include competition from larger, more established players in the agricultural inputs industry, such as Bayer and Corteva.
What are the key factors to evaluate for BIOX?
Bioceres Crop Solutions Corp. (BIOX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. These products can enhance crop yields and improve soil health, aligning with the growing demand for sustainable agricultural practices. Not financial advice.
How frequently does BIOX data refresh on this page?
BIOX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BIOX's recent stock price performance?
Bioceres Crop Solutions Corp. (BIOX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOX overvalued or undervalued right now?
Bioceres Crop Solutions Corp. (BIOX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 11 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com